Synergistic combination comprising roflumilast and (r,r) - formoterol
The invention relates to the combined administration of roflumilast and R,R-formoterol for the treatment of respiratory tract disorders.
1 . Combined use of roflumilast and R,R-formoterol in preventing the symptoms of, or treating a respiratory tract disorder in humans.
2 . Combined use of roflumilast and R,R-formoterol in preventing the symptoms of, or treating a respiratory tract disorder in humans, which comprises administering roflumilast in a daily dosage of from 100 to 500 μg and R,R-formoterol in a daily dosage of from 10 to 120 μg.
3 . Medicament suited for the combined use according to claim 1 or 2 , which comprises roflumilast and R,R-formoterol in fixed or free combination.
4 . Medicament according to claim 3 , which is a fixed oral combination.
5 . Medicament according to claim 3 , which is a fixed oral combination containing roflumilast in a daily dosage of from 100 to 500 μg and R,R-formoterol in a daily dosage of from 10 to 120 μg.
6 . Medicament according to claim 3 , which is a free combination comprising roflumilast in an oral formulation and R,R-formoterol in a formulation suited for administration by inhalation.
7 . Medicament according to claim 3 , which is a free combination comprising roflumilast in an oral formulation in a daily dosage of from 100 to 500 μg and R,R-formoterol in a formulation suited for administration by inhalation in a daily dosage of from 10 to 50 μg.
8 . Medicament according to claim 3 , which is a medicament pack containing two pack units with roflumilast in an oral formulation and R,R-formoterol in a formulation suited for administration by inhalation.
9 . Method for preventing or reducing the onset of symptoms of a pulmonary disease, or treating or reducing the severity of a pulmonary disease by administering to a patient in need thereof an effective amount of roflumilast and R,R-formoterol either in a single combined form, separately, or separately and sequentially where the sequential administration is close in time, or remote in time.
10 . Method according to claim 9 , which comprises administering roflumilast in a daily dosage of from 100 to 500 μg and R,R-formoterol in a daily dosage of from 10 to 50 μg.
11 . Medicament pack, containing roflumilast as active ingredient, which contains a description that roflumilast can be administered, for reducing the onset of symptoms of a pulmonary disease, or for treating or reducing the severity of a pulmonary disease, together with R,R-formoterol sequentially, where the sequential administration is close in time, or remote in time in any order whatever.
12 . Medicament pack, containing R,R-formoterol as active ingredient, which contains a description that R,R-formoterol can be administered, for reducing the onset of symptoms of a pulmonary disease, or for treating or reducing the severity of a pulmonary disease, together with roflumilast sequentially, where the sequential administration is close in time, or remote in time in any order whatever.